RNS Number: 4797D GSK PLC 15 October 2025

GSK plc (the 'Company') Transaction notification

	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Emma Walmsley		
b)	Position/status	Chief Executive Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	r, emission allowance market participant, auction platform, on monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D	793	
3.	(ii) each type of trans	tails of the transaction(s): section to be repeated for (i) each type of instrument; each type of transaction; (iii) each date; and (iv) each place where insaction(s) has been conducted		
a)		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the	Increase in notional interest in Ordinary Shares following the reinvestment of dividends paid to shareholders on 9 October 2025 or Ordinary Shares held in the Company's Deferred Annual Bonus Plar		
b)	transaction		paid to shareholders on 9 October 202	25 on
c)	transaction	Ordinary Shares held ir	paid to shareholders on 9 October 202	25 on
,	transaction	Ordinary Shares held ir	paid to shareholders on 9 October 20, the Company's Deferred Annual Bonus	25 on
,	transaction	Ordinary Shares held in Price(s)	paid to shareholders on 9 October 20: the Company's Deferred Annual Bonus Volume(s)	25 on
,	transaction	Ordinary Shares held in Price(s) £16.4000	paid to shareholders on 9 October 20; the Company's Deferred Annual Bonus Volume(s) 1,355	25 or
,	transaction	Ordinary Shares held in Price(s) £16.4000	paid to shareholders on 9 October 20; the Company's Deferred Annual Bonus Volume(s) 1,355 1,531	25 or
c)	rransaction Price(s) and volume(s) Aggregated information Aggregated volume	Ordinary Shares held in Price(s) £16.4000	paid to shareholders on 9 October 20; the Company's Deferred Annual Bonus Volume(s) 1,355 1,531	25 or
c)	Aggregated information Aggregated volume Price	Ordinary Shares held in Price(s) £16.4000 £16.4000	paid to shareholders on 9 October 20; the Company's Deferred Annual Bonus Volume(s) 1,355 1,531	25 on

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Julie Brown	
b)	Position/status	Chief Financial Officer	
c)	Initial notification/ amendment	Initial notification	

2.		ils of the issuer, emission allowance market participant, auction platform, ioneer or auction monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	(ii) each type of trans	Details of the transaction(s): section to be repeated for (i) each type of instrument; ii) each type of transaction; (iii) each date; and (iv) each place where ransaction(s) has been conducted		
a)		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)		investment of dividends	nterest in Ordinary Shares following the respect to shareholders on 9 October 2025 on the Company's Deferred Annual Bonus Pla	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.4000	680	
		£16.4000	584	
d)	Aggregated information			
	Aggregated volume Price	1,264 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exchanç	ge (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Diana Conrad		
b)	Position/status	Chief People Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s) Price(s)	Volume(s)	
		£16.4000	152	
		£16.4000	386	
		£16.4000	246	

d)	Aggregated information	
	Aggregated volume Price	784 £16.4000
e)	Date of the transaction	2025-10-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/pers	son closely associate	ed with them ('PCA')	
a)	Name	James Ford		
b)	Position/status	SVP and Group Gene	ral Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	, emission allowance market participant, auction platform, on monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1I	D793	
3.		ction(s): section to be repeated for (i) each type of instrument; asaction; (iii) each date; and (iv) each place where een conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.4000	239	
		£16.4000	237	
		£16.4000	391	
d)	Aggregated information			
	55 5	867 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exchar	nge (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	

c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	emission allowance market participant, auction platform, n monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	(ii) each type of trans	Details of the transaction(s): section to be repeated for (i) each type of instrument; ii) each type of transaction; (iii) each date; and (iv) each place where ransaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)		Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.4000	242	
		£16.4000	149	
		£16.4000	133	
d)	Aggregated information			
	1 1991 - 9-11-1	524 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exchanç	ge (XLON)	

a)	Name	Luke Miels		
b)	Position/status	Chief Commercial Officer		
c)	Initial notification/ amendment	Initial notification		
2.		etails of the issuer, emission allowance market participant, auction platform, uctioneer or auction monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
_	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
3.	(ii) each type of trar	nsaction; (iii) each date; and (iv) each place where		
	(ii) each type of trar	nsaction; (iii) each date; and (iv) each place where		
a)	(ii) each type of transaction(s) has be Description of the	ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 Increase in notional interest in Ordinary Shares following the reinvestment of dividends paid to shareholders on 9 October 2025 on		
a) b)	(ii) each type of trar transaction(s) has be Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 Increase in notional interest in Ordinary Shares following the reinvestment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		

		£16.4000	578 727	
d)	Aggregated information			
	Aggregated volume Price	1,670 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exchange	e (XLON)	

1.	Details of PDMR/pe	IR/person closely associated with them ('PCA')		
a)	Name	Shobie Ramakrishr	nan	
b)	Position/status	Chief Digital and Technology Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044		
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 on ADSs held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s) Price(s)	Volume(s)	
		43.4400	119	
		43.4400	112	
		43.4400	186	
d)	Aggregated information			
d)		417 43.4400		
d) e)	information Aggregated volume			

a)	Name	David Redfern		
b)	Position/status	President, Corporate	Development	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	emission allowance market participant, auction platform, n monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transac (ii) each type of tran transaction(s) has be	lction(s): section to be repeated for (i) each type of instrument; asaction; (iii) each date; and (iv) each place where een conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.4000	463	
		£16.4000	334	
		£16.4000	211	
حا/	Aggregated			
d)	Aggregated information			
	Aggregated volume Price	1,008 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Excha	ange (XLON)	
<u> </u>	1	<u> </u>		

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Regis Simard		
b)	Position/status	President, Global Supply Chain		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		

b)	transaction	investment of dividend	nterest in Ordinary Shares fo s paid to shareholders on 9 Oo n the Company's Deferred Annu	ctober 2025 on
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.4000	309	
		£16.4000	557	
		£16.4000	268	
d)	Aggregated information			
		1,134 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exchan	ge (XLON)	

1.	Details of PDMR/pers	R/person closely associated with them ('PCA')				
a)	Name	Philip Thomson				
b)	Position/status	President, Global Affairs				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,			
a)	Name	GSK plc				
b)	LEI		93			
3.	(ii) each type of trans	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	investment of dividends	erest in Ordinary Shares following the re- paid to shareholders on 9 October 2025 or the Company's Deferred Annual Bonus Plar			
c)	Price(s) and volume(s)	Price(s)	Volume(s)			
		£16.4000	188			
		£16.4000	311			
		£16.4000	175			
d)	Aggregated information		·			
	Aggregated volume Price	674 £16.4000				
e)	Date of the transaction	2025-10-10				

f)	Place of the transaction	London Stock Exchange (XLON)

	Details of PDMR/per	Is of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse		
b)	Position/status	CEO, ViiV Healthcare a	nd President, Global Health, GS	šK
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auction		narket participant, auction pla	atform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D7	93	
3.		saction; (iii) each date	repeated for (i) each type of ii ; and (iv) each place where	nstrument;
		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
a)	Description of the financial instrument)
a) b)		ISIN: GB00BN7SWP63 Increase in notional interpretation interpretation in the investment of dividends		wing the re
,	financial instrument Nature of the	ISIN: GB00BN7SWP63 Increase in notional infinvestment of dividends Ordinary Shares held in	terest in Ordinary Shares follo paid to shareholders on 9 Octo	wing the re
b)	Nature of the transaction	ISIN: GB00BN7SWP63 Increase in notional intinvestment of dividends Ordinary Shares held in	terest in Ordinary Shares follo paid to shareholders on 9 Octo the Company's Deferred Annual	wing the re
b)	Nature of the transaction	ISIN: GB00BN7SWP63 Increase in notional infinestment of dividends Ordinary Shares held in Price(s)	terest in Ordinary Shares follo paid to shareholders on 9 Octo the Company's Deferred Annual Volume(s)	wing the re
b)	Nature of the transaction	ISIN: GB00BN7SWP63 Increase in notional infinvestment of dividends Ordinary Shares held in Price(s) £16.4000	terest in Ordinary Shares follo paid to shareholders on 9 Octo the Company's Deferred Annual Volume(s) 427	wing the re
b)	Nature of the transaction	ISIN: GB00BN7SWP63 Increase in notional infinestment of dividends Ordinary Shares held in Price(s) £16.4000	terest in Ordinary Shares follo paid to shareholders on 9 Octo the Company's Deferred Annual Volume(s) 427 482	wing the re
b)	financial instrument Nature of the transaction Price(s) and volume(s) Aggregated	ISIN: GB00BN7SWP63 Increase in notional infinestment of dividends Ordinary Shares held in Price(s) £16.4000	terest in Ordinary Shares follo paid to shareholders on 9 Octo the Company's Deferred Annual Volume(s) 427 482	wing the re
b) c)	Inancial instrument Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	ISIN: GB00BN7SWP63 Increase in notional infinestment of dividends Ordinary Shares held in Price(s) £16.4000 £16.4000	terest in Ordinary Shares follo paid to shareholders on 9 Octo the Company's Deferred Annual Volume(s) 427 482	wing the re

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Tony Wood		
b)	Position/status	Chief Scientific Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.		action(s): section to be repeated for (i) each type of instrument; insaction: (iii) each date: and (iv) each place where		

	transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	investment of dividence	interest in Ordinary Shares following the re- ls paid to shareholders on 9 October 2025 on in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.4000	594	
		£16.4000	202	
		£16.4000	271	
d)	Aggregated information			
	Aggregated volume Price	1,067 £16.4000		
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exchar	ige (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Emma Walmsley		
b)	Position/status	Chief Executive Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		nce market participant, auct	ion platform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYL	.O1D793	
3.		saction; (iii) each	o be repeated for (i) each typ a date; and (iv) each place w	
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period		
c)	Price(s) and volume(s	Price(s)	Volume(s)	
		£16.4000	4,590.351	

	1			
		£16.4000	4,196.389	
d)	information Aggregated volume	N/A (single transa 8,786.741 £16.4000	ction)	
e)	Date of the transaction	2025-10-10		
f)	Place of the transaction	London Stock Exc	change (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	David Redfern			
b)	Position/status	President Corporate Dev	President Corporate Development		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auction		narket participant, auction platform,		
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D7	93		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrumer (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction		Shares following the re-investment of olders on 9 October 2025 on Ordinary A		
c)	Price(s) and volume(s	Price(s)	Volume(s)		
		£16.3499	20		
d)	Aggregated information	N/A (single transaction)			
	Aggregated volume Price				
e)	Date of the transaction	2025-10-10			
f)	Place of the transaction	London Stock Exchange	(XLON)		

1.	Details of PDMR/p	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte		
b)	Position/status	Company Secretary		

-,						
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer auctioneer or auction	r, emission allowance market participant, auction platform, on monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO	1D793			
3.		nsaction; (iii) each d	pe repeated for (i) each type of instrument; ate; and (iv) each place where			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held within an ISA				
c)	Price(s) and volume(s) Price(s)	Volume(s)			
		£16.3499	17			
d)	Aggregated information	N/A (single transaction)				
	Aggregated volume Price					
e)	Date of the transaction	2025-10-10				
f)	Place of the transaction	London Stock Excha	ange (XLON)			

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFMSAIEISEES